The DOI matches its Crossref record.
Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s
Open accessAbstract
BACKGROUND: Fat gain after antiretroviral therapy (ART) occurs, and its association with protease inhibitors (PIs) is unclear. METHODS: Peripheral and central fat depots and lean mass were measured using standardized and centrally read abdominal CT scans and whole-body dual-energy absorptiometry scans over a 96-week period in human immunodeficiency virus (HIV)-infected treatment-naive participants. The patients were randomized to tenofovir-emtricitabine (TDF/FTC) plus atazanavir-ritonavir (ATV/r), darunavir-ritonavir (DRV/r), or raltegravir (RAL) in ACTG A5260s, a substudy of A5257. Within arm changes were assessed with signed-rank tests. The 96-week percentage changes in fat and lean mass in the 2 PI arms were not different, thus the PI arms were combined and compared to the RAL arm. Associations between baseline biomarkers and changes in body composition were assessed. All analyses used linear regression models. RESULTS: 328 patients were randomized (90% male, 44% white non-Hispanic). The median age was 36 years, HIV-1 RNA 4.6 log10 copies/mL, and CD4 349 cells/μL. Overall, at week 96, increases in limb fat (13.4%), subcutaneous (19.9%) and visceral abdominal fat (25.8%), trunk fat (18%), and lean mass (1.8%) were apparent (P < .001 for changes within each arm). Changes for all fat and lean outcomes were not different between the PI arms or between the RAL and the combined PI arms. Higher baseline HIV-1 RNA levels were associated with greater gains in peripheral and central fat. CONCLUSIONS: In treatment-naive participants initiating ART with TDF/FTC, no differences in lean mass and regional fat were found with RAL when compared with ATV/r or DRV/r over 96 weeks. CLINICAL TRIALS REGISTRATION: NCT00811954 and NCT00851799.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sax, P. E., Erlandson, K. M., Lake, J. E., Mccomsey, G. A., Orkin, C., Esser, S., Brown, T. T., Rockstroh, J. K., Wei, X., Carter, C. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz999 · Cited by 768
Self-citationFeinstein, M. J., Hsue, P. Y., Benjamin, L. A., Bloomfield, G. S., Currier, J. S., Freiberg, M. S., Grinspoon, S. K., Levin, J., Longenecker, C. T., Post, W. S., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000695 · Cited by 658
Self-citationGreater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy
Bourgi, K., Rebeiro, P. F., Turner, M., Castilho, J. L., Hulgan, T., Raffanti, S. P., Koethe, J. R., & Sterling, T. R. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz407 · Cited by 327
Hodes, R. J., Sierra, F., Austad, S. N., Epel, E., Neigh, G. N., Erlandson, K. M., Schafer, M. J., LeBrasseur, N. K., Wiley, C., Campisi, J., et al. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13299 · Cited by 132
Eckard, A. R., Wu, Q., Sattar, A., Ansari-Gilani, K., Labbato, D., Foster, T., Fletcher, A. A., Adekunle, R. O., & McComsey, G. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00150-5 · Cited by 55
Self-citation
Metadata
- Authors
- McComsey, G. A., Moser, C., Currier, J., Ribaudo, H. J., Paczuski, P., Dubé, M. P., Kelesidis, T., Rothenberg, J., Stein, J. H., & Brown, T. T.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-01-20
- Volume
- 62
- Issue
- 7
- Pages
- 853-862
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2311215932
- Cited by
- 161
- References
- 0
- FWCI
- 29.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. https://app.cochat.ai/papers/10.1093/cid/ciw017
- The paper
- McComsey, G. A., Moser, C., Currier, J., Ribaudo, H. J., Paczuski, P., Dubé, M. P., Kelesidis, T., Rothenberg, J., Stein, J. H., & Brown, T. T. (2016). Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciw017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.